Take home message: An alternative model for the origin of syn-and metachronous tumors that better explain the existing genetic data is described.
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Introduction
Urothelial carcinomas (UC) originate from the epithelial cells of the inner lining of the bladder wall. The majority of the tumors is papillary and confined to the urothelial mucosa (stage Ta) or to the lamina propria (stage T1) whereas the remaining are muscle invasive (T2-T4). Most Ta tumors are of low grade (G1 or G2), rarely progress, and are associated with a favorable prognosis whereas high grade Ta (TaG3) and T1 tumors represent a significant risk of tumor progression. Carcinoma in situ, Tis, is a flat lesion commonly found in association with malignant tumors and is generally believed to be the precursor of invasive cancer.
Patients with Ta and T1 tumors are typically treated by transurethral resection, often combined with intravesical chemo-or immunotherapy. However, up to 70% of the patients show recurrences after treatment making a lifelong follow-up by regular cystoscopy necessary. This growth pattern of UC gives an opportunity to investigate the early stages of tumor development as both recurrences and multiple tumors from the same patients frequently are available. Particularly, "re-initiation" of the transforming process in the same genetic and environmental background may be studied. Furthermore, the topology of the bladder organ has made it possible to analyze non-cancerous tissue in patients with UC in a systematic way.
In the present review the data on genetic changes in normal, premalignant, as well as in synchronous and metachronous UC tumors will be examined. Suggested hypotheses for the origin of synchronous and metachronous tumors will be evaluated in view of the existing data and possible alternative explanations will be put forward.
Syn-and metachronous tumors are clonally related.
Three major hypotheses have been proposed to explain both the origin of multiple and of recurring tumors; field cancerization [1] , seeding [2] , and intra epithelial migration [3] . The field-cancerization model assumes that the urothelium is exposed to mutational stress, due to e.g., waist products collected in the urine, and that accumulation of mutations in individual cells eventually will lead the initiation of a cancer process. In this model tumors are caused by independent events and will consequently have different cellular origins and be non-clonal.
The idea behind intraluminal seeding is that recurrent and multiple tumors arise from the shredding of cells from a primary tumor and that shred cells are re-implanted in the normal mucosa in which they initiate the growth of a new tumor. As the syn-or metachronous tumors in this scenario will originate from a primary tumor, the resulting tumors will be clonally related. In the intra epithelial migration model tumor cells are believed to spread through the normal mucosa by migration. The resulting tumors will be clonal as they originate from the 4 same primary tumor. In addition, if intra epithelial migration occurs one is expected to find tumor cells located in the normal urothelium between tumor foci.
As one of the major questions regarding syn-or metachronous tumors is their clonal relationship, this has been the topic for many investigations. A factor complicating the interpretations of the published results is that the term clonality is not always used with the same meaning and that different molecular tools used to establish clonality does not always measure the same thing. Clonality could mean that tumor B has originated from cells in tumor A, however, it could also mean that cells in tumors A and B share the same cellular origin but has not evolved from each other. In the first situation genetic changes present in tumor A is expected to be present also in tumor B, as B represents a development of cells in tumor A. In Figure 1 show inactivation of the same X chromosome, as indicated, they are likely to be clonal even though they do not share all late genetic changes. Sidransky et al. [4] and Li et al. [5] used X-inactivation studies to establish the clonal relationship among syn-and metachronous tumors from a total of 23 patients. In each case the tumors from the same patient did show X-inactivating patterns consistent with a monoclonal origin.
Other investigators have used loss of heterozygosity analysis (LOH), that determine the loss of specific gene alleles, chromosomal analysis using fluorescent in situ hybridization (FISH), or gene mutation analyses to perform similar investigations e.g., Simon et al. [6] showed that 32 tumors from six patients showed patterns signifying monoclonality. In some investigations it has not been possible to establish clonal relationship of syn-or metachronous tumors in all patients [2, 7, 8, 9] . However, as LOH analysis was used in these investigations and LOH events may occur late in tumor development, these findings do not exclude a clonal relationship among the differing tumors. Irrespective if these latter cases represent examples of true oligoclonality or not, the major part of investigated tumors from the same patients does show molecular patterns consistent with having a monoclonal origin. Hence, it may be concluded that the vast majority of syn-and metachronous tumors show a clonal relationship and that the model of field-cancerization is not an appropriate explanation for tumor recurrence and multiple tumors.
Premalignant lesions and morphologically normal urothelium in patients with urothelial carcinoma show genetic changes.
Almost all human malignancies are characterized by having chromosomal changes.
Furthermore, there is a correlation between the numbers of chromosomal changes and the aggressiveness of the cancer. Chromosomal changes believed to occur early in UC development and thus prevalent in low grade and low stage tumors are loss of chromosome 9 and gain of the long arm of chromosome 1 whereas chromosomal changes believed to occur late in tumor development include loss of the short arms of chromosomes 3, 4, and 8, and the long arm of chromosome 5 [10] . There is growing evidence that chromosomal changes characteristic of UC are already present in premalignant lesions such as hyperplasia and dysplasia. Hartmann et al. [11] demonstrated that hyperplasias showed monosomies or partial losses of chromosome 9 and that the same genetic alterations were seen in the concomitant 6 papillary tumors. In addition, in two out of six investigated patients, chromosome 9 deletions were also detected in the normal epithelium adjacent to the tumor. Oberman et al. [12] showed by comparative genome hybridization (CGH), which identifies patterns of chromosomal gains and losses, and LOH analyses that flat urothelial hyperplasias showed chromosomal changes shared by concomitant papillary tumors. Chow et al. [13] also used CGH to show that hyperplasias shared changes with the concomitant papillary tumors. These findings were verified by FISH that also detected losses of chromosome 9 in normal epithelium. Furthermore, dysplasias show chromosomal and genetic changes highly similar to what is seen in cancer in situ [14] . Hence, it may be concluded that precancerous lesions show the same genetic alterations as overt cancers.
As noted, the presence of cancer related mutations is not limited to precancerous lesions but is also seen in morphologically normal urothelium in patients with UC. Cianciulli et al. [15] showed by FISH analyses that morphologically normal urothelium from patients with UC demonstrated genetic aberrations common to those of bladder cancer. Particularly loss of chromosome 9 and gain of chromosome 7 was seen in the tumors, the proximal, and the distal mucosa. Steidl et al. [16] showed by FISH analyzes that tumors and their adjacent normal urothelium were affected by similar chromosomal aberrations. Genomic imbalances in normal urotheliun have also repeatedly been shown by CGH and LOH [17, 18, 19] e.g., Stoehr et al. [20] found LOH of chromosomes 9 and 8 in histologically normal epithelium in five out of fifteen patients. Thirty cases with no history of UC were used as controls and no LOH was found. This shows that the normal urothelium in patients with UC is different from normal urothelium from individuals with no signs of UC. The genetic alterations seen in normal and premalignant cells are not limited to chromosomal changes but also include gene mutations and epigenetic changes [6, 18, 21] e.g., normal urothelium, preneoplastic lesions, as well as tumors from the same patient may share the same TP53 mutation [22] . As a prerequisite to detect chromosomal changes by LOH and by CGH, and gene mutations by DNA sequencing is that a large proportion if the investigated material share the same changes, substantial proportions, and not just occasional cells, of the normal tissue show genetic alterations.
Hence, genetically aberrant but morphologically non-cancerous cells appear to surround the growth of carcinomas at high densities.
Histologic and genetic mapping studies represent a more thorough approach to study the urothelium in patients with UC. In these studies the complete surface of a cystectomized bladder is divided into a large number of sections organized into a coordinate system. Each section is then evaluated both by histopathological and by genetical means ultimately creating [24] and for chromosome 13 and RB1 mutations [25] . In a similar analysis Stoehr et al. [26] showed that TP53 mutations were detected in regions with preneoplastic lesions as well as in normal urothelium and Simon et al. [6] showed that synchronous tumors with TP53 mutations were located within continuous areas of normal urotheliun with TP53 mutations, whereas tumors with a normal TP53 gene were located within areas of urothelium showing no mutations.
Genetic and histologic mapping has also shown that LOH for chromosomes 4, 8, 9, 11, and 17 may be detected in the normal urothelium demonstrating that extensive karyotypic evolution may occur already in morphologically normal cells [27] . The suggested lack of correlation between the chronological appearance of tumors and genetic progression is also supported by the fact that recurring tumors may be of lower grade than the preceding ones [29] and that TP53 and to acute myeloid leukemia (AML). The chronic phase would include the induction of selfrenewal capacity and ultimately in a field-defect, and the acute phase a local transformation of preneoplastic cells to overt tumors. In this scenario the frequency by which recurrences occur would be dependent on both the size as well as the genetic heterogeneity [41] of the affected fields and not strictly on the genetic changes in the preceding tumors.
Conclusions
One of the key challenges in the management of UC is the high frequency of recurrences. 
